Author:
Simão Vinhosa Nunes Nágela,do Nascimento Erivelton Alessandro,Luz Katia,de Andrade Martins Wolney
Publisher
Springer International Publishing
Reference57 articles.
1. Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, et al. Epidemiology of cardiac amyloidosis–associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Hear Fail. 2019;12(6):1–9.
2. Ash S, Shorer E, Ramgobin D, et al. Cardiac amyloidosis—a review of current literature for the practicing physician. Clin Cardiol. 2021;44(3):322.
3. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases Heart failure and cardiomyopathies. Eur Heart J. 2021;17:1554–68.
4. Mohammed SF, Mirzoyev A, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Hear Fail. 2014;2(2):113–22.
5. van den Berg MP, Mulder BA, Klaassen SHC, et al. Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. Eur Heart J. 2019;40:1287–93.